Chimeric Antigen Receptor Therapy (CAR-T) is the latest breakthrough in oncology care. Simply put, it involves taking a patient’s cells, sending them to the drug manufacturer where they are re-engineered, and then infusing them back into the patient to attack the patient’s cancer. CAR-T will impact many core aspects of revenue integrity, including reimbursement.
Whether you’re new to the National Association of Healthcare Revenue Integrity (NAHRI) website or just looking to learn more about what’s available to you, our website demo can help.
Use this sample resource as a guide to outline the steps that must be taken to comply with obtaining the correct patient status order for patients who are scheduled for an inpatient-only procedure.
I believe that avoiding denials in the first place is the way to utilize our revenue cycle resources, especially our human resources. The more times we have to touch or rework a claim, the lower the value our final reimbursement becomes. Our goal is to get it right the first time. This can best be accomplished by education with our clinical staff in a way that they can relate and understand the general coding and billing concepts.
